Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
NCT ID: NCT00333788
Last Updated: 2018-08-07
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
233 participants
INTERVENTIONAL
2006-10-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease
NCT00356408
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
NCT00160524
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
NCT00308581
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
NCT00160706
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
NCT00552344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Certolizumab pegol 400 mg
400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
Certolizumab pegol (CDP870)
400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Certolizumab pegol (CDP870)
400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 \[NCT00308581\] study
* Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment
* Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gainesville, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Indianapolis, Indiana, United States
Louisville, Kentucky, United States
Baton Rouge, Louisiana, United States
Lincoln, Nebraska, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Charleston, North Carolina, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Oklahoma City, Oklahoma, United States
Portland, Oregon, United States
Charleston, South Carolina, United States
Germantown, Tennessee, United States
Nashville, Tennessee, United States
Houston, Texas, United States
Seattle, Washington, United States
Innsbruck, , Austria
Vienna, , Austria
Bonheiden, , Belgium
Brussels, , Belgium
Genk, , Belgium
Ghent, , Belgium
Leuven, , Belgium
Liège, , Belgium
Roeselare, , Belgium
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
London, Ontario, Canada
Toronto, Ontario, Canada
Calgary, , Canada
Clichy, , France
Lille, , France
Nice, , France
Paris, , France
Pessac, , France
Berlin, , Germany
Hamburg, , Germany
Herne, , Germany
Kiel, , Germany
Leipzig, , Germany
Minden, , Germany
Munich, , Germany
München, , Germany
Bologna, , Italy
Milan, , Italy
Padua, , Italy
Palermo, , Italy
Roma, , Italy
Torino, , Italy
Eindhoven, , Netherlands
Heerlen, , Netherlands
Barcelona, , Spain
Madrid, , Spain
Santiago de Compostela, , Spain
Seville, , Spain
Valencia, , Spain
Stockholm, , Sweden
Bern, , Switzerland
Lausanne, , Switzerland
Bristol, , United Kingdom
London, , United Kingdom
Oxford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-001729-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
C87046
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.